Loading..

Fate Therapeutics, Inc. (FATE) Report Analysis

Corporate Events

Neutral

Fate Therapeutics, Inc. Announces Expansion of ...

2022-06-28 11:00:00

Fate Therapeutics, Inc. announced that it has expanded its off-the-shelf, iPSC-derived, cell-based cancer immunotherapy collaboration with ONO...

Neutral

Fate Therapeutics, Inc. has filed a Shelf Regis...

2022-06-09 00:00:00

Fate Therapeutics, Inc. has filed a Shelf Registration in the amount of $230.47 million. Security Name: Common Stock Securities Offered: 9...

Neutral

Fate Therapeutics, Inc. Presents at 2022 Jeffer...

2022-06-04 01:03:00

Fate Therapeutics, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-10-2022 09:00 AM. Venue: Marriott Marquis, New York City,...

Neutral

Fate Therapeutics, Inc. Presents at H.C. Wainwr...

2022-05-07 02:03:00

Fate Therapeutics, Inc. Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 . Venue: Fontainebleau Miami Beach Hotel, 4...

Neutral

Fate Therapeutics, Inc. Presents at H.C. Wainwr...

2022-05-06 20:01:00

Fate Therapeutics, Inc. Presents at H.C. Wainwright Annual Global Life Sciences Conference, May-24-2022 07:00 AM.

Neutral

Fate Therapeutics, Inc., Annual General Meeting...

2022-04-25 20:08:00

Fate Therapeutics, Inc., Annual General Meeting, Jun 09, 2022, at 08:00 US Eastern Standard Time. Agenda: To discuss election of three class I...

Neutral

Fate Therapeutics, Inc., Q1 2022 Earnings Call,...

2022-04-22 12:00:00

Fate Therapeutics, Inc., Q1 2022 Earnings Call, May 04, 2022

Neutral

Fate Therapeutics, Inc. to Report Q1, 2022 Resu...

2022-04-22 12:00:00

Fate Therapeutics, Inc. announced that they will report Q1, 2022 results on May 04, 2022

Neutral

Fate Therapeutics, Inc. Presents at 2022 Fc Rec...

2022-04-21 15:29:00

Fate Therapeutics, Inc. Presents at 2022 Fc Receptor and IgG Targeted Therapies Conference, Apr-26-2022 . Venue: Boston, Massachusetts, United...

Neutral

Hanson Wade Limited, 2022 Fc Receptor and IgG T...

2022-04-21 09:39:00

Hanson Wade Limited, 2022 Fc Receptor and IgG Targeted Therapies Conference, Apr 26, 2022 through Apr 28, 2022. Venue: Boston, Massachusetts, ...

Neutral

Fate Therapeutics, Inc. Presents at Bank of Ame...

2022-03-22 05:03:00

Fate Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Conference, May-12-2022 09:20 AM. Venue: Encore Hotel, 3121 Las Vegas Blvd...

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright Glo...

2022-02-28 18:21:00

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami B...

Neutral

Bank of America Corporation, Bank of America 20...

2022-02-17 10:42:00

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vega...

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare...

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New Yor...

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright Ann...

2022-02-14 20:39:00

H.C. Wainwright & Co., LLC, H.C. Wainwright Annual Global Life Sciences Conference, May 23, 2022 through May 25, 2022.

Neutral

Fate Therapeutics, Inc. Presents at 4th Annual ...

2022-02-02 00:00:00

Fate Therapeutics, Inc. Presents at 4th Annual Guggenheim Oncology Day, Feb-09-2022 11:00 AM.

Neutral

Guggenheim Securities, LLC, 4th Annual Guggenhe...

2022-01-24 11:50:00

Guggenheim Securities, LLC, 4th Annual Guggenheim Oncology Day, Feb 09, 2022 through Feb 11, 2022.

Positive

Fate Therapeutics, Inc Presents Positive Clinic...

2021-12-14 22:29:00

Fate Therapeutics, Inc. presented positive clinical data from the dose-escalation stage of its ongoing Phase 1 study of FT516 for patients wit...

Positive

Fate Therapeutics Showcases Positive Interim Ph...

2021-12-13 21:31:00

Fate Therapeutics, Inc. showcased positive interim Phase 1 data from the company’s FT596 program for patients with relapsed /refractory B-cell...

Positive

Fate Therapeutics Highlights Positive Durabilit...

2021-12-13 14:01:00

Fate Therapeutics, Inc. presented positive clinical data from the dose-escalation stage of its ongoing Phase 1 study of FT516 for patients wit...

Neutral

Fate Therapeutics, Inc. Presents at 63rd Americ...

2021-12-08 22:44:00

Fate Therapeutics, Inc. Presents at 63rd American Society of Hematologists Annual Meeting & Exposition, Dec-14-2021 08:00 AM. Venue: Georgia W...

Neutral

Fate Therapeutics, Inc. Presents at Piper Sandl...

2021-11-22 15:06:00

Fate Therapeutics, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, United States.

Neutral

Fate Therapeutics, Inc. Presents at 12th Annual...

2021-11-11 13:06:00

Fate Therapeutics, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM. Venue: London, United Kingdom.

Neutral

Fate Therapeutics, Inc. Presents at Piper Sandl...

2021-11-11 13:06:00

Fate Therapeutics, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-23-2021 10:00 AM.

Neutral

Fate Therapeutics, Inc. Presents at 4th Annual ...

2021-11-11 13:06:00

Fate Therapeutics, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 09:40 AM.

Neutral

Fate Therapeutics, Inc. - Special Call

2021-11-09 14:09:00

To highlight its emerging pipeline of off-the-shelf, multiplexed-engineered, iPSC-derived NK cell programs for the treatment of solid tumors

Neutral

Fate Therapeutics, Inc. has filed a Shelf Registration.

2021-11-04 00:00:00

Fate Therapeutics, Inc. has filed a Shelf Registration. Security Name: Common Stock Security Name: Preferred Stock Security Name: Deb...

Negative

Fate Therapeutics, Inc. has filed a Follow-on E...

2021-11-04 00:00:00

Fate Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $350 million. Security Name: Common Stock Security Type: Co...

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global...

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, Unit...

Neutral

Fate Therapeutics, Inc., Q3 2021 Earnings Call,...

2021-10-25 12:00:00

Fate Therapeutics, Inc., Q3 2021 Earnings Call, Nov 04, 2021

Neutral

Piper Sandler Companies, Piper Sandler 33rd Ann...

2021-10-25 10:00:00

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021.

Neutral

Fate Therapeutics, Inc. Presents at 6th Annual ...

2021-10-07 19:58:00

Fate Therapeutics, Inc. Presents at 6th Annual Viral Safety and Viral Clearance Summit, Apr-26-2022 . Venue: Hyatt Centric Fisherman's Wharf, ...

Neutral

Charles River Laboratories International, Inc.,...

2021-10-07 19:44:00

Charles River Laboratories International, Inc., 6th Annual Viral Safety and Viral Clearance Summit, Apr 26, 2022 through Apr 27, 2022. Venue: ...

Positive

Fate Therapeutics, Inc. Announces Publication o...

2021-09-15 12:00:00

Fate Therapeutics, Inc. announced the publication of preclinical data demonstrating that its off-the-shelf, multiplexed-engineered, iPSC-deriv...

Neutral

Fate Therapeutics, Inc. Presents at Cantor Glob...

2021-09-04 12:50:00

Fate Therapeutics, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-29-2021 10:40 AM. Venue: New York, United States.

Neutral

Fate Therapeutics, Inc. Presents at Oppenheimer...

2021-09-04 12:47:00

Fate Therapeutics, Inc. Presents at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep-22-2021 04:35 PM.

Neutral

Fate Therapeutics, Inc. Presents at H.C. Wainwr...

2021-09-04 12:37:00

Fate Therapeutics, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York Pala...

Neutral

Fate Therapeutics, Inc. Presents at Morgan Stan...

2021-09-04 12:26:00

Fate Therapeutics, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-10-2021 11:00 AM. Venue: New Windsor, United States.

Neutral

Fate Therapeutics, Inc. Presents at Citi’s 16th...

2021-09-01 19:46:00

Fate Therapeutics, Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-08-2021 . Venue: New York, United States.

Neutral

Fate Therapeutics, Inc. Presents at Baird Globa...

2021-08-26 17:20:00

Fate Therapeutics, Inc. Presents at Baird Global Healthcare Conference 2021, Sep-15-2021 12:15 PM. Speakers: Edward J. Dulac, CFO & Principal ...

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCO...

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Positive

Fate Therapeutics, Inc. Announces Positive Inte...

2021-08-19 20:01:00

Fate Therapeutics, Inc. highlighted positive interim clinical data from the Company’s FT516 and FT596 programs for patients with relapsed /ref...

Neutral

Fate Therapeutics, Inc. Presents at World Vacci...

2021-08-18 15:33:00

Fate Therapeutics, Inc. Presents at World Vaccine & Immunotherapy Congress West Coast 2021, Nov-30-2021 02:10 PM. Venue: Loews Coronado Bay Re...

Neutral

Robert W. Baird & Co. Incorporated, Baird Globa...

2021-08-10 13:03:00

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021.

Negative

Fate Therapeutics Appoints Yuan Xu to its Board...

2021-08-05 16:32:00

Fate Therapeutics, Inc. announced the appointment of Yuan Xu, Ph.D., to its Board of Directors as an independent director. Dr. Xu brings to Fa...

Negative

Fate Therapeutics, Inc Appoints Yuan Xu as Clas...

2021-08-04 13:21:00

On August 3, 2021 Fate Therapeutics, Inc. Board appointed Yuan Xu, Ph.D. to the Board as a Class II director. Dr. Xu was appointed to a newly ...

Positive

Fate Therapeutics Announces Treatment of First ...

2021-08-02 20:50:00

Fate Therapeutics, Inc. announced that the first patient has been treated with FT819, an off-the-shelf chimeric antigen receptor (CAR) T-cell ...

Neutral

American Society Of Hematology, 63rd American S...

2021-07-31 11:04:00

American Society Of Hematology, 63rd American Society of Hematologists Annual Meeting & Exposition, Dec 11, 2021 through Dec 15, 2021. Venue: ...

Neutral

Fate Therapeutics, Inc. Presents at Wells Fargo...

2021-07-22 14:24:00

Fate Therapeutics, Inc. Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-09-2021 10:40 AM. Speakers: Edward J. Dulac, CFO & Pri...

Neutral

Wells Fargo Securities, LLC, Wells Fargo 2021 V...

2021-07-22 09:08:00

Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021.

Neutral

Terrapinn Holdings Ltd, World Vaccine & Immunot...

2021-07-22 01:45:00

Terrapinn Holdings Ltd, World Vaccine & Immunotherapy Congress West Coast 2021, Nov 30, 2021 through Dec 02, 2021. Venue: Loews Coronado Bay R...

Neutral

Oppenheimer & Co. Inc., Oppenheimer Fall Health...

2021-07-21 14:31:00

Oppenheimer & Co. Inc., Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep 20, 2021 through Sep 23, 2021.

Neutral

Fate Therapeutics, Inc. - Special Call

2021-07-16 12:09:00

To discuss interim Phase 1 clinical data from its FT596 and FT516 programs for the treatment of relapsed / refractory B-cell lymphomas

Neutral

Fate Therapeutics, Inc., Q2 2021 Earnings Call,...

2021-07-15 20:01:00

Fate Therapeutics, Inc., Q2 2021 Earnings Call, Aug 04, 2021

Neutral

Fate Therapeutics, Inc. Announces Expansion of Solid Tumor Collaboration with Ono Pharmaceutical for Off-the-Shelf, iPSC-derived CAR NK and CAR T-Cell Cancer Immunotherapies

2022-06-28 11:00:00

Fate Therapeutics, Inc. announced that it has expanded its off-the-shelf, iPSC-derived, cell-based cancer immunotherapy collaboration with ONO Pharmaceutical Co. Ltd. (ONO) to include the development of chimeric antigen receptor NK cell collaboration candidates. In addition, as part of the collaboration’s expansion, ONO will contribute novel binding domains targeting a second solid tumor antigen. Under the original Collaboration and Option Agreement entered into between Fate and ONO in September 2018, ONO has contributed novel binding domains targeting an initial solid tumor antigen, and Fate is currently conducting preclinical development of a multiplexed-engineered, iPSC-derived CAR T-cell product candidate for solid tumors. Under the terms of the amended Collaboration and Option Agreement, Fate will advance iPSC-derived CAR NK and CAR T-cell product candidates to a pre-defined preclinical milestone, at which point ONO has an option to assume responsibility for worldwide development and commercialization with Fate retaining the right to jointly develop and commercialize in the United States and Europe. Fate retains all rights of manufacture of collaboration products on a global basis. Fate will continue to receive committed research funding from ONO during the preclinical option period, and is eligible to receive a preclinical option exercise fee as well as clinical, regulatory and commercialization milestone payments from ONO in connection with the development and commercialization of each product candidate. In addition, Fate is eligible to receive tiered royalties on net sales by ONO of each product candidate in the ONO territory. The Company’s proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that are designed to be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with other cancer treatments. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company’s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment. As a result, the Company’s platform is uniquely designed to overcome numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 350 issued patents and 150 pending patent applications.

Neutral

Fate Therapeutics, Inc. has filed a Shelf Registration in the amount of $230.47 million.

2022-06-09 00:00:00

Fate Therapeutics, Inc. has filed a Shelf Registration in the amount of $230.47 million. Security Name: Common Stock Securities Offered: 9,500,000 Transaction Features: ESOP Related Offering

Neutral

Fate Therapeutics, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-10-2022 09:00 AM

2022-06-04 01:03:00

Fate Therapeutics, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-10-2022 09:00 AM. Venue: Marriott Marquis, New York City, New York, United States.

Neutral

Fate Therapeutics, Inc. Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022

2022-05-07 02:03:00

Fate Therapeutics, Inc. Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 . Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States.

Neutral

Fate Therapeutics, Inc. Presents at H.C. Wainwright Annual Global Life Sciences Conference, May-24-2022 07:00 AM

2022-05-06 20:01:00

Fate Therapeutics, Inc. Presents at H.C. Wainwright Annual Global Life Sciences Conference, May-24-2022 07:00 AM.

Neutral

Fate Therapeutics, Inc., Annual General Meeting, Jun 09, 2022

2022-04-25 20:08:00

Fate Therapeutics, Inc., Annual General Meeting, Jun 09, 2022, at 08:00 US Eastern Standard Time. Agenda: To discuss election of three class III directors; to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022; to approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement; to approve the Fate Therapeutics, Inc. 2022 Stock Option and Incentive Plan; and to transact other business matters.

Neutral

Fate Therapeutics, Inc., Q1 2022 Earnings Call, May 04, 2022

2022-04-22 12:00:00

Fate Therapeutics, Inc., Q1 2022 Earnings Call, May 04, 2022

Neutral

Fate Therapeutics, Inc. to Report Q1, 2022 Results on May 04, 2022

2022-04-22 12:00:00

Fate Therapeutics, Inc. announced that they will report Q1, 2022 results on May 04, 2022

Neutral

Fate Therapeutics, Inc. Presents at 2022 Fc Receptor and IgG Targeted Therapies Conference, Apr-26-2022

2022-04-21 15:29:00

Fate Therapeutics, Inc. Presents at 2022 Fc Receptor and IgG Targeted Therapies Conference, Apr-26-2022 . Venue: Boston, Massachusetts, United States. Speakers: Ryan Bjordahl, Director, Cancer Immunotherapy.

Neutral

Hanson Wade Limited, 2022 Fc Receptor and IgG Targeted Therapies Conference, Apr 26, 2022 through Apr 28, 2022

2022-04-21 09:39:00

Hanson Wade Limited, 2022 Fc Receptor and IgG Targeted Therapies Conference, Apr 26, 2022 through Apr 28, 2022. Venue: Boston, Massachusetts, United States.

Neutral

Fate Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Conference, May-12-2022 09:20 AM

2022-03-22 05:03:00

Fate Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Conference, May-12-2022 09:20 AM. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States. Speakers: Edward J. Dulac, CFO & Principal Accounting Officer, J. Scott Wolchko, Founder, CEO, President & Director.

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022

2022-02-28 18:21:00

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States.

Neutral

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022

2022-02-17 10:42:00

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States.

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright Annual Global Life Sciences Conference, May 23, 2022 through May 25, 2022

2022-02-14 20:39:00

H.C. Wainwright & Co., LLC, H.C. Wainwright Annual Global Life Sciences Conference, May 23, 2022 through May 25, 2022.

Neutral

Fate Therapeutics, Inc. Presents at 4th Annual Guggenheim Oncology Day, Feb-09-2022 11:00 AM

2022-02-02 00:00:00

Fate Therapeutics, Inc. Presents at 4th Annual Guggenheim Oncology Day, Feb-09-2022 11:00 AM.

Neutral

Guggenheim Securities, LLC, 4th Annual Guggenheim Oncology Day, Feb 09, 2022 through Feb 11, 2022

2022-01-24 11:50:00

Guggenheim Securities, LLC, 4th Annual Guggenheim Oncology Day, Feb 09, 2022 through Feb 11, 2022.

Positive

Fate Therapeutics, Inc Presents Positive Clinical Data from the Dose-Escalation Stage of Ongoing Phase 1 Study of FT516

2021-12-14 22:29:00

Fate Therapeutics, Inc. presented positive clinical data from the dose-escalation stage of its ongoing Phase 1 study of FT516 for patients with relapsed /refractory B-cell lymphoma (BCL) at the 63rd American Society of Hematology Annual Meeting and Exposition. FT516 is the Company’s universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with a novel high-affinity, non-cleavable CD16 (hnCD16) Fc receptor, which is designed to maximize antibody-dependent cellular cytotoxicity (ADCC), a potent anti-tumor mechanism by which NK cells recognize, bind and kill antibody-coated cancer cells. In addition, the Company announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to FT516 for the treatment of relapsed /refractory diffuse large B-cell lymphoma (DLBCL). The RMAT program provides all of the benefits of the fast track and breakthrough therapy designation programs such as early interactions with the FDA to discuss potential pathways for accelerated approval. The Phase 1 clinical trial in relapsed /refractory BCL is assessing FT516 in an off-the-shelf treatment regimen of up to two cycles, with each cycle consisting of three days of conditioning chemotherapy (500 mg/m2 of cyclophosphamide and 30 mg/m2 of fludarabine), a single-dose of rituximab (375 mg/m2), and three weekly doses of FT516 each with IL-2 cytokine support. The FT516 treatment regimen is designed to be administered in the outpatient setting. Patients in the dose-escalation stage had received a median of 3.5 prior lines of therapy and a median of three prior lines containing CD20-targeted therapy. As of the data cutoff date of October 18, 2021, four patients in the second dose cohort of 90 million cells per dose, seven patients in the third dose cohort of 300 million cells per dose, and seven patients in the fourth dose cohort of 900 million cells per dose were evaluable for assessment of safety and efficacy (n=18). Of these 18 patients, 10 patients were naïve to treatment with autologous CD19-targeted chimeric antigen receptor (CAR) T-cell therapy and eight patients were previously treated with autologous CD19-targeted CAR T-cell therapy, including three patients in the fourth dose cohort that were refractory to CAR T-cell therapy.

Positive

Fate Therapeutics Showcases Positive Interim Phase 1 Data from FT596 Off-the-shelf, iPSC-derived CAR NK Cell Program for Relapsed / Refractory B-cell Lymphoma at 2021 ASH Annual Meeting

2021-12-13 21:31:00

Fate Therapeutics, Inc. showcased positive interim Phase 1 data from the company’s FT596 program for patients with relapsed /refractory B-cell lymphoma (BCL) at the 63rdAmerican Society of Hematology (ASH) Annual Meeting and Exposition. FT596 is the company’s off-the-shelf, multi-antigen targeted, iPSC-derived natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with three anti-tumor functional modalities: a proprietary chimeric antigen receptor (CAR) optimized for NK cell biology that targets B-cell antigen CD19; a novel high-affinity, non-cleavable CD16 (hnCD16) Fc receptor that has been modified to prevent its down-regulation and to enhance its binding to tumor-targeting antibodies; and an IL-15 receptor fusion (IL-15RF) that augments NK cell activity. The ongoing Phase 1 study in relapsed /refractory BCL is assessing a single dose of FT596 as monotherapy (Monotherapy Arm) and in combination with a single dose of rituximab (375 mg/m2) (Combination Arm) following three days of conditioning chemotherapy (500 mg/m2 of cyclophosphamide and 30 mg/m2 of fludarabine). Certain patients are eligible for re-treatment with a second, single-dose cycle. The ASH presentation (Session 704—Cellular Immunotherapies: Expanding Targets and Cellular Sources for Immunotherapies, Abstract 823) includes clinical data from 25 evaluable patients for safety (n=12 in Monotherapy Arm; n=13 in Combination Arm) in the first, second, and third single-dose cohorts of 30 million, 90 million, and 300 million cells, respectively, of which 24 patients were also evaluable for efficacy (n=12 in Monotherapy Arm; n=12 in Combination Arm), as of the data cutoff date of October 11, 2021. These 25 patients had received a median of four prior lines of therapy and a median of two prior lines containing CD20-targeted therapy. Of the 25 patients, 15 patients (60%) had aggressive B-cell lymphoma, 15 patients (60%) were refractory to most recent prior therapy, and 8 patients (32%) were previously treated with autologous CD19-targeted CAR T-cell therapy. Subsequent to the data cutoff date for the ASH presentation, an additional patient in the third single-dose cohort of the Combination Arm was evaluable for initial anti-tumor response, and seven patients in the fourth single-dose cohort of 900 million cells (n=1 in Monotherapy Arm; n=6 in Combination Arm) were evaluable for safety and initial anti-tumor response. Single-dose, Single-cycle Response Data: In the second, third, and fourth dose cohorts of the Monotherapy and Combination Arms comprising a total of 26 patients, 18 patients (69%) achieved an objective response, including 12 patients (46%) that achieved a complete response, on Day 29 following a single dose of FT596 (see Table 1). Nine of these 26 patients were previously treated with autologous CD19-targeted CAR T-cell therapy and, of these nine patients, six achieved an objective response (67%) on Day 29 following a single dose of FT596. Notably, in the third and fourth dose cohorts of the Combination Arm comprising a total of 12 patients, nine patients (75%) achieved an objective response, including seven patients (58%) that achieved a complete response, on Day 29 following a single dose of FT596. Durability of Response Data: The ASH presentation includes durability of response data from 13 responding patients in the second and third single-dose cohorts of 90 million cells and 300 million cells (n=9 in Monotherapy Arm; n=10 in Combination Arm). As of the data cutoff date of October 11, 2021, 10 patients continued in ongoing response, including three patients in ongoing complete response at least six months from initiation of treatment; two patients reached six months in complete response and subsequently had disease progression; and one patient had disease progression prior to six months. Of these 13 responding patients: Monotherapy Arm (n=7 responding patients). Five patients, all of whom were treated with a second FT596 single-dose cycle with the consent of the U.S. Food and Drug Administration (FDA), continued in ongoing response at a median follow-up of 4.1 months, including one patient in ongoing complete response at 8.1 months; one patient, who was treated with only one FT596 single-dose cycle, reached six months in complete response and subsequently had disease progression at 6.5 months; and one patient, who was treated with only one FT596 single-dose cycle, had disease progression at 1.7 months; Combination Arm (n=6 responding patients). Five patients, all of whom were treated with a second FT596 single-dose cycle with the consent of the FDA, continued in ongoing response at a median follow-up of 4.6 months, including two patients in ongoing complete response at 6.0 and 10.8 months; and one patient, who was treated with a second FT596 single-dose cycle with the consent of the FDA, reached six months in complete response and subsequently had disease progression at 6.7 months; aCD19 = autologous CD19-targeted CAR T-cell therapy; Aggressive = diffuse large B-cell lymphoma, Grade 3b follicular lymphoma, Richter’s transformation, and high-grade B-cell lymphoma; CR = complete response; Indolent = splenic diffuse red pulp small B-cell lymphoma, non-Grade 3b follicular lymphoma, Waldenstrom’s macroglobulinemia, and small lymphocytic lymphoma; M = million; OR = objective response. Safety Data: The FT596 treatment regimens were well tolerated, including in those patients treated with a second, single-dose cycle. No dose-limiting toxicities, and no treatment-emergent adverse events (TEAEs) of any grade of immune effector cell-associated neurotoxicity syndrome (ICANS) or graft-versus-host disease (GvHD) were observed. Three low-grade adverse events (two Grade 1, one Grade 2) of cytokine release syndrome (CRS) were reported, which were of limited duration and resolved without intensive care treatment. The company has initiated enrollment of a two-dose treatment schedule in the Combination Arm, with FT596 administered on Day 1 and Day 15 at 900 million cells per dose. Patients with clinical benefit following administration of the first two-dose cycle are eligible for re-treatment with a second two-dose cycle. Additionally, patients with clinical response are eligible for re-treatment following disease progression.

Positive

Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-Cell Lymphoma and Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to Ft516 for Relapsed / Refractory DLBCL

2021-12-13 14:01:00

Fate Therapeutics, Inc. presented positive clinical data from the dose-escalation stage of its ongoing Phase 1 study of FT516 for patients with relapsed /refractory B-cell lymphomaat the 63rdAmerican Society of Hematology Annual Meeting and Exposition. FT516 is the Company’s universal, off-the-shelf natural killer cell product candidate derived from a clonal master induced pluripotent stem cell line engineered with a novel high-affinity, non-cleavable CD16. Fc receptor, which is designed to maximize antibody-dependent cellular cytotoxicity, a potent anti-tumor mechanism by which NK cells recognize, bind and kill antibody-coated cancer cells. In addition, the company announced that the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to FT516 for the treatment of relapsed /refractory diffuse large B-cell lymphoma. The RMAT program provides all of the benefits of the fast track and breakthrough therapy designation programs such as early interactions with the FDA to discuss potential pathways for accelerated approval. The Phase 1 clinical trial in relapsed /refractory BCL is assessing FT516 in an off-the-shelf treatment regimen of up to two cycles, with each cycle consisting of three days of conditioning chemotherapy, a single-dose of rituximab, and three weekly doses of FT516 each with IL-2 cytokine support. The FT516 treatment regimen is designed to be administered in the outpatient setting. Patients in the dose-escalation stage had received a median of 3.5 prior lines of therapy and a median of three prior lines containing CD20-targeted therapy. As of the data cutoff date of October 18, 2021, four patients in the second dose cohort of 90 million cells per dose, seven patients in the third dose cohort of 300 million cells per dose, and seven patients in the fourth dose cohort of 900 million cells per dose were evaluable for assessment of safety and efficacy. Of these 18 patients, 10 patients were naïve to treatment with autologous CD19-targeted chimeric antigen receptor T-cell therapy and eight patients were previously treated with autologous CD19-targeted CAR T-cell therapy, including three patients in the fourth dose cohort that were refractory to CAR T-cell therapy. Of the ten patients naïve to treatment with CAR T-cell therapy, eight patients achieved an objective response, including five patients that achieved a complete response. Three of eight patients previously treated with CAR T-cell therapy achieved an objective response, all of whom achieved a complete response. In each relapsed /refractory BCL disease setting (aggressive BCL naïve to CAR T-cell therapy; indolent BCL naïve to CAR T-cell therapy; aggressive BCL previously treated with CAR T-cell therapy), responses were observed in each of the second, third, and fourth dose cohorts. All 11 responding patients in the second, third, and fourth dose cohorts continued in ongoing response at three months following initiation of treatment. As of the data cutoff date, eight patients continued in ongoing response at a median follow-up of 8.3 months: Three of five patients with aggressive BCL naïve to CAR T-cell therapy continued in ongoing response, with two patients in ongoing response beyond six months and one patient in ongoing response at 4.6 months; Three of five patients with indolent BCL naïve to CAR T-cell therapy continued in ongoing response, with two patients in ongoing response beyond six months and one patient in ongoing response at 3.7 months; and Two of eight patients with aggressive BCL previously treated with CAR T-cell therapy continued in ongoing response, with responses ongoing at 4.6 and 8.3 months. The median duration of response in each of the relapsed /refractory BCL disease settings for all responding patients had not been reached. No dose-limiting toxicities, and no FT516-related serious adverse events, were observed. The FT516 treatment regimen was well tolerated, and no treatment-emergent adverse events of any grade of cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or graft-versus-host disease were reported by investigators. Grade 3 or greater TEAEs related to FT516 were observed in two patients (neutrophil count decreased; and neutropenia and thrombocytopenia). There were no discontinuations due to adverse events. In addition, no evidence of anti-product T- or B-cell mediated host-versus-product alloreactivity was observed, supporting the potential to safely administer up to six doses of FT516 in the outpatient setting without the need for patient matching.

Neutral

Fate Therapeutics, Inc. Presents at 63rd American Society of Hematologists Annual Meeting & Exposition, Dec-14-2021 08:00 AM

2021-12-08 22:44:00

Fate Therapeutics, Inc. Presents at 63rd American Society of Hematologists Annual Meeting & Exposition, Dec-14-2021 08:00 AM. Venue: Georgia World Congress Center, Atlanta, Georgia, United States.

Neutral

Fate Therapeutics, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021

2021-11-22 15:06:00

Fate Therapeutics, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, United States.

Neutral

Fate Therapeutics, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM

2021-11-11 13:06:00

Fate Therapeutics, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM. Venue: London, United Kingdom.

Neutral

Fate Therapeutics, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-23-2021 10:00 AM

2021-11-11 13:06:00

Fate Therapeutics, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-23-2021 10:00 AM.

Neutral

Fate Therapeutics, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 09:40 AM

2021-11-11 13:06:00

Fate Therapeutics, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 09:40 AM.

Neutral

Fate Therapeutics, Inc. - Special Call

2021-11-09 14:09:00

To highlight its emerging pipeline of off-the-shelf, multiplexed-engineered, iPSC-derived NK cell programs for the treatment of solid tumors

Neutral

Fate Therapeutics, Inc. has filed a Shelf Registration.

2021-11-04 00:00:00

Fate Therapeutics, Inc. has filed a Shelf Registration. Security Name: Common Stock Security Name: Preferred Stock Security Name: Debt Securities Security Name: Warrants Security Name: Units Transaction Features: Omnibus/Universal Shelf Registration

Negative

Fate Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $350 million.

2021-11-04 00:00:00

Fate Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $350 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, United States.

Neutral

Fate Therapeutics, Inc., Q3 2021 Earnings Call, Nov 04, 2021

2021-10-25 12:00:00

Fate Therapeutics, Inc., Q3 2021 Earnings Call, Nov 04, 2021

Neutral

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021

2021-10-25 10:00:00

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021.

Neutral

Fate Therapeutics, Inc. Presents at 6th Annual Viral Safety and Viral Clearance Summit, Apr-26-2022

2021-10-07 19:58:00

Fate Therapeutics, Inc. Presents at 6th Annual Viral Safety and Viral Clearance Summit, Apr-26-2022 . Venue: Hyatt Centric Fisherman's Wharf, San Francisco, California, United States. Speakers: Mark Plavsic, Chief Technical Officer.

Neutral

Charles River Laboratories International, Inc., 6th Annual Viral Safety and Viral Clearance Summit, Apr 26, 2022 through Apr 27, 2022

2021-10-07 19:44:00

Charles River Laboratories International, Inc., 6th Annual Viral Safety and Viral Clearance Summit, Apr 26, 2022 through Apr 27, 2022. Venue: Hyatt Centric Fisherman's Wharf, San Francisco, California, United States.

Positive

Fate Therapeutics, Inc. Announces Publication of FT538 Preclinical Data Demonstrating Enhanced Serial Killing and Functional Persistence without Cytokine Support

2021-09-15 12:00:00

Fate Therapeutics, Inc. announced the publication of preclinical data demonstrating that its off-the-shelf, multiplexed-engineered, iPSC-derived NK cell product candidate FT538 exhibits significantly enhanced serial killing and functional persistence compared to peripheral blood NK cells. The superior anti-tumor activity of FT538 was attributable to its novel engineered components, including the knockout of CD38 and the expression of IL-15/IL-15R fusion protein, which were shown to improve metabolic fitness, increase resistance to oxidative stress, and induce transcription of proteins that control NK cell activation and effector function. The data were published in Cell Stem Cell in an online article entitled Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy. The studies in the Cell Stem Cell publication were conducted as part of a collaboration between scientists at Fate Therapeutics and the laboratory of Jeffrey S. Miller, M.D., University of Minnesota, and were led by Frank Cichocki, Ph.D., University of Minnesota. The Miller laboratory has previously shown that a rare subset of NK cells with memory-like properties that arise in response to cytomegalovirus, known as adaptive NK cells, have a genome-wide epigenetic profile and recall response that parallel cytotoxic effector CD8+ T cells. These adaptive NK cells persist long term, exhibit a unique metabolic profile with elevated mitochondrial oxidative phosphorylation and glycolysis as well as increased levels of ATP, and have enhanced cytotoxicity. The peer-reviewed paper describes preclinical studies showing that FT538 shares metabolic, transcriptional, and functional features with adaptive NK cells. The data demonstrate that FT538 persists in vivo at high levels for more than six weeks in the absence of cytokine support after adoptive transfer, whereas adoptively-transferred peripheral blood NK cells required the co-infusion of either IL-2 or IL-15 to achieve low-level persistence for up to two weeks. Additionally, in sequential killing assays, FT538 was shown to have robust serial killing and functional persistence, which were not observed with peripheral blood NK cells. FT538 also incorporates a novel high-affinity, non-cleavable CD16 Fc receptor as a third functional component, which was shown to mediate potent in vivo anti-tumor activity in combination with the CD38-targeted monoclonal antibody daratumumab against MM.1S myeloma cells. FT538 is being investigated in a multi-dose phase 1 clinical trial for the treatment of acute myeloid leukemia and in combination with daratumumab for the treatment of multiple myeloma (NCT04614636). In addition, the company has initiated patient enrollment in a multi-dose phase 1 clinical trial of FT538 in combination with certain monoclonal antibodies targeting EGFR, HER2, and PDL1 for the treatment of solid tumors.

Neutral

Fate Therapeutics, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-29-2021 10:40 AM

2021-09-04 12:50:00

Fate Therapeutics, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-29-2021 10:40 AM. Venue: New York, United States.

Neutral

Fate Therapeutics, Inc. Presents at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep-22-2021 04:35 PM

2021-09-04 12:47:00

Fate Therapeutics, Inc. Presents at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep-22-2021 04:35 PM.

Neutral

Fate Therapeutics, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM

2021-09-04 12:37:00

Fate Therapeutics, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York Palace Hotel, New York City, New York, United States.

Neutral

Fate Therapeutics, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-10-2021 11:00 AM

2021-09-04 12:26:00

Fate Therapeutics, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-10-2021 11:00 AM. Venue: New Windsor, United States.

Neutral

Fate Therapeutics, Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-08-2021

2021-09-01 19:46:00

Fate Therapeutics, Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-08-2021 . Venue: New York, United States.

Neutral

Fate Therapeutics, Inc. Presents at Baird Global Healthcare Conference 2021, Sep-15-2021 12:15 PM

2021-08-26 17:20:00

Fate Therapeutics, Inc. Presents at Baird Global Healthcare Conference 2021, Sep-15-2021 12:15 PM. Speakers: Edward J. Dulac, CFO & Principal Accounting Officer.

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Positive

Fate Therapeutics, Inc. Announces Positive Interim Clinical Data from its FT596 and FT516 Off-the-Shelf

2021-08-19 20:01:00

Fate Therapeutics, Inc. highlighted positive interim clinical data from the Company’s FT516 and FT596 programs for patients with relapsed /refractory B-cell lymphoma. FT516 is the Company’s universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with a novel high-affinity, non-cleavable CD16 (hnCD16) Fc receptor, which is designed to maximize antibody-dependent cellular cytotoxicity (ADCC), a potent anti-tumor mechanism by which NK cells recognize, bind and kill antibody-coated cancer cells. The Company’s FT596 program incorporates both the hnCD16 Fc receptor and a chimeric antigen receptor (CAR) targeting CD19, which is designed to enable multi-antigen targeting of tumor cells, as well as an IL-15 receptor fusion (IL-15RF) to enhance NK cell activity and survival. FT596 Program: The ongoing clinical trial in relapsed /refractory B-cell lymphoma is assessing a single dose of FT596 as monotherapy (Monotherapy Arm) and in combination with a single dose of rituximab (375 mg/m2) (Combination Arm) following three days of conditioning chemotherapy (500 mg/m2 of cyclophosphamide and 30 mg/m2 of fludarabine). As of the data cutoff date of June 25, 2021, 10 patients in the Monotherapy Arm and 10 patients in the Combination Arm were evaluable for assessment of safety and efficacy in the first, second, and third dose cohorts of 30 million cells (n=3 each), 90 million cells (n=4 each), and 300 million cells (n=3 each), respectively. Patients had received a median of four prior lines of therapy and a median of 2.5 prior lines containing CD20-targeted therapy. Of the 20 patients, 12 patients (60%) had aggressive B-cell lymphoma, 10 patients (50%) were refractory to most recent prior therapy, and seven patients (35%) were previously treated with autologous CD19-targeted CAR T-cell therapy. In the second and third single-dose cohorts of the Monotherapy and Combination Arms comprising a total of 14 patients, 10 of 14 patients (71%) achieved an objective response, including seven patients (50%) that achieved a complete response (CR), as assessed by PET-CT scan per Lugano 2014 criteria on Day 29 following FT596 dosing. Eight of 10 patients (80%) that had not previously received CD19-targeted CAR T-cell therapy achieved an objective response, including five patients (50%) that achieved CR. Two of four patients (50%) that had previously received CD19-targeted CAR T-cell therapy, both of whom were treated in the Combination Arm, achieved a CR. In the first single-dose cohorts of the Monotherapy and Combination Arms comprising a total of six patients, only one patient achieved an objective response, suggesting dose-response treatment effects for FT596. The ongoing dose-escalation study of FT596 is currently enrolling patients in the fourth single-dose cohort of 900 million cells in each arm. The FT596 treatment regimens were well tolerated. No dose-limiting toxicities, and no treatment-emergent adverse events (TEAEs) of any grade of immune effector cell-associated neurotoxicity syndrome (ICANS) or graft-versus-host disease (GVHD) were observed. Two low-grade adverse events (one Grade 1, one Grade 2) of cytokine release syndrome (CRS) were reported, both of which occurred concurrently with other confounding clinical events and resolved on the same day of onset. FT596 Patient Case StudiesThe multi-antigen targeting functionality of FT596 is designed to uniquely address tumor heterogeneity and overcome antigen escape, and has the potential to drive responses in patients that might not effectively be treated with single-antigen targeted modalities, such as monoclonal antibodies, bispecific engagers and CAR T-cell therapies. The following are two case studies from the clinical trial: Patient 2014. In the Monotherapy Arm, a 78-year-old woman with splenic diffuse red pulp small B cell lymphoma, who had received four prior therapies including three CD20-targeted regimens, presented with CD19High and CD20Null tumor cells indicative of CD20 antigen escape. The patient achieved a CR after single-dose, single-cycle treatment at 90 million FT596 cells as monotherapy with resolution of all metabolically active disease including clearance of baseline bone marrow involvement, demonstrating the activity of the product candidate’s CAR receptor. Patient 2016. The Combination Arm included a 68-year-old male with transformed indolent lymphoma who had received six prior therapies, including three anti-CD20-containing regimens and autologous CD19-targeted CAR T-cell therapy. The patient achieved a CR after single-dose, single-cycle treatment at 300 million FT596 cells in combination with rituximab with resolution of all metabolically active disease, suggesting that the product candidate’s hnCD16 receptor can synergize with rituximab to drive complete responses in patients that have progressed following CD19-targeted CAR T-cell therapy. Re-treatment with Second FT596 Cycle: The FT596 protocol currently allows for the re-treatment of eligible patients with a second, single-dose cycle subject to consent of the U.S. Food and Drug Administration (FDA). All requests by the Company for re-treatment were approved by the FDA. Of note, based on review of data submitted to date to the FDA, the Company is amending its FT596 clinical protocol at the FDA’s recommendation to allow for re-treatment with a second FT596 cycle without requiring the agency’s consent. In second and third single-dose cohorts of the Monotherapy and Combination Arms as of the data cutoff date, four patients with CR at the end of the first single-dose cycle were re-treated, all of whom remained in CR following disease assessment at the end of the second cycle, and an additional four patients were re-treated and had not yet been assessed for response. The second, single-dose FT596 cycle was well tolerated, and no events of any grade of CRS, ICANS, or GVHD were observed.

Neutral

Fate Therapeutics, Inc. Presents at World Vaccine & Immunotherapy Congress West Coast 2021, Nov-30-2021 02:10 PM

2021-08-18 15:33:00

Fate Therapeutics, Inc. Presents at World Vaccine & Immunotherapy Congress West Coast 2021, Nov-30-2021 02:10 PM. Venue: Loews Coronado Bay Resort, San Diego, California, United States. Speakers: Bahram Valamehr, Chief Research & Development Officer.

Neutral

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021

2021-08-10 13:03:00

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021.

Negative

Fate Therapeutics Appoints Yuan Xu to its Board of Directors

2021-08-05 16:32:00

Fate Therapeutics, Inc. announced the appointment of Yuan Xu, Ph.D., to its Board of Directors as an independent director. Dr. Xu brings to Fate Therapeutics over 25 years of discovery, development, manufacturing, and commercial experience in the global biopharmaceuticals business, most recently serving as the Chief Executive Officer and Board Member of Legend Biotech Corporation where she led the company's efforts in advancing ciltacabtagene autoleucel (cilta-cel) from proof-of-concept in 2018 to BLA preparation in 2020.

Negative

Fate Therapeutics, Inc Appoints Yuan Xu as Class II Director

2021-08-04 13:21:00

On August 3, 2021 Fate Therapeutics, Inc. Board appointed Yuan Xu, Ph.D. to the Board as a Class II director. Dr. Xu was appointed to a newly created vacancy on the Board resulting from the Board Increase. From March 2018 to August 2020, Dr. Xu served as chief executive officer and as a director of Legend Biotech Corporation (Legend"), where she played a leading role in the company's initial public offering, clinical development of the autologous CAR T-cell therapy cilta-cel, and partnership with Janssen. Dr. Xu brings to Fate Therapeutics over 25 years of discovery, development, manufacturing, and commercial experience in the global biophar maceuticals business, most recently serving as the Chief Executive Officer and Board Member of Legend Biotech Corporation where she led the company's efforts in advancing ciltacabtagene autoleucel (cilta-cel) from proof-of-concept in 2018 to BLA preparation in 2020.

Positive

Fate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-Cell Therapy

2021-08-02 20:50:00

Fate Therapeutics, Inc. announced that the first patient has been treated with FT819, an off-the-shelf chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies. FT819 is the first-ever CAR T-cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line, a renewable cell source that enables mass production of high quality, allogeneic CAR T cells with greater product consistency, off-the-shelf availability, and broader patient accessibility. FT819 is engineered with several first-of-kind features designed to improve the safety and efficacy of CAR T-cell therapy. FT819 was designed to specifically address several limitations associated with the current generation of patient- and donor-derived CAR T-cell therapies. Under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering and Head, Gene Expression and Gene Transfer Laboratory, the Company incorporated several first-of-kind features into FT819 including: Use of a clonal master engineered iPSC line as the starting cell source, which enables CAR T cells to be mass produced and delivered off-the-shelf for broad patient access; Incorporation of a novel 1XX CAR signaling domain, which has been shown to extend T-cell effector function without eliciting exhaustion as described in the journal Nature Medicine (https://doi.org/10.1038/s41591-018-0290-5); Insertion of the CAR transgene directly into the T-cell receptor alpha constant (TRAC) locus, which has been shown to promote uniform CAR expression and enhanced T-cell potency as described in the journal Nature (https://doi.org/10.1038/nature21405); and Complete bi-allelic disruption of T-cell receptor (TCR) expression for the prevention of graft-versus-host disease (GvHD), a potentially life-threatening complication associated with allogeneic T-cell therapy. The multi-center Phase 1 clinical trial of FT819 is designed to determine the recommended Phase 2 dose and schedule of FT819 and assess its safety and clinical activity in adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and B-cell lymphomas (BCL). Three treatment regimens will be independently evaluated for each type of malignancy in dose escalation: Regimen A as a single dose of FT819; Regimen B as a single dose of FT819 with IL-2 cytokine support; and Regimen C as three fractionated doses of FT819. For each indication and regimen, dose-expansion cohorts may be enrolled to further evaluate the clinical activity of FT819. The first patient with relapsed /refractory ALL was enrolled in Regimen A and received a dose of 90 million cells.

Neutral

American Society Of Hematology, 63rd American Society of Hematologists Annual Meeting & Exposition, Dec 11, 2021 through Dec 15, 2021

2021-07-31 11:04:00

American Society Of Hematology, 63rd American Society of Hematologists Annual Meeting & Exposition, Dec 11, 2021 through Dec 15, 2021. Venue: Georgia World Congress Center, Atlanta, Georgia, United States.

Neutral

Fate Therapeutics, Inc. Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-09-2021 10:40 AM

2021-07-22 14:24:00

Fate Therapeutics, Inc. Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-09-2021 10:40 AM. Speakers: Edward J. Dulac, CFO & Principal Accounting Officer, J. Scott Wolchko, Founder, CEO, President & Director.

Neutral

Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021

2021-07-22 09:08:00

Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021.

Neutral

Terrapinn Holdings Ltd, World Vaccine & Immunotherapy Congress West Coast 2021, Nov 30, 2021 through Dec 02, 2021

2021-07-22 01:45:00

Terrapinn Holdings Ltd, World Vaccine & Immunotherapy Congress West Coast 2021, Nov 30, 2021 through Dec 02, 2021. Venue: Loews Coronado Bay Resort, San Diego, California, United States.

Neutral

Oppenheimer & Co. Inc., Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep 20, 2021 through Sep 23, 2021

2021-07-21 14:31:00

Oppenheimer & Co. Inc., Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep 20, 2021 through Sep 23, 2021.

Neutral

Fate Therapeutics, Inc. - Special Call

2021-07-16 12:09:00

To discuss interim Phase 1 clinical data from its FT596 and FT516 programs for the treatment of relapsed / refractory B-cell lymphomas

Neutral

Fate Therapeutics, Inc., Q2 2021 Earnings Call, Aug 04, 2021

2021-07-15 20:01:00

Fate Therapeutics, Inc., Q2 2021 Earnings Call, Aug 04, 2021

Fundamental Summary

The financials published by Fate Therapeutics for Q1 were weak and discouraging. Their growth, value, and income factors indicate a poor execution and strategy, which isn't generating exciting growth. Typically, results like these translate into sustained negative momentum and strong downward pressure on stock price. Therefore, we assessed them with a rating of 45 and a UNDERPERFORM recommendation.

Fate Therapeutics reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 65.69 million compared to USD 45.09 million a year ago. Basic loss per share from continuing operations was USD 0.68 compared to USD 0.48 a year ago.

Business Description

Fate Therapeutics, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics was incorporated in 2007 and is headquartered in San Diego, California.

Sector Overview

Fate Therapeutics is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Fate Therapeutics's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 858.4 -6.8% 70
Liabilities 225.0 -7.3% 63
Price to Book 3.9 -52.7% 45
Cash & Equivalents 64.7 -51.5% 39
Equity 633.4 -6.7% 54
EBITDA -219.9 -13.3% 52
Total Revenues 63.1 13.0% 45
Parameter Value Change Score
Return on Equity -32.7 18.1% 61
Net Cashflow -41.7 -23.4% 64
Capital Expenditure -56.8 -12.0% 55
Asset Turnover 0.1 -8.4% 48
Free Cashflow -2.7 -19.5% 52

* All values are TTM

The below chart reflects Fate Therapeutics's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Fate Therapeutics's peer average final assessment score stands on 58.0, Fate Therapeutics's score is 45.

  •  FATE
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 0 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 1 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 2 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 3 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 4 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 5 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 6 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 7 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 8 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 9 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 10 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 11 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 12 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 13 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 14 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 15 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 16 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 17 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 18 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 19 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 20 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 22 1
Amgen Inc. 130.1B 69 78 81
Hold
77
77 23 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 24 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 26 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 27 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 28 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 30 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 31 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 32 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 33 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 34 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 35 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 36 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 37 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 38 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 39 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 40 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 41 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 42 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 43 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 44 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 46 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 47 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 48 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 50 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 52 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 53 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 54 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 55 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 56 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 57 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 58 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 59 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 60 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 61 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 62 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 63 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 65 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 66 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 68 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 69 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 70 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 71 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 72 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 73 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 74 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 75 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 76 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 77 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 78 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 79 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 80 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 81 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 82 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 83 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 84 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 85 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 92 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 93 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 94 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 95 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Fate Therapeutics's stock is now priced below its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a negative setup in the near, medium, and long-term. The company is trading near it's 12-month low, which signals it struggle to keep above it support price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Fate Therapeutics's stock doesn't strongly signal being overbought or oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 31.

Bearish 31
Close Price 24.75
52W Low 17.78
52W High 95.73
5D MA 25.4
50D MA 25.39
200D MA 43.03
MACD -0.0
RSI 47.08
STOCH 77.27

Balance Sheet Analysis

Fate Therapeutics's balance sheet factors had several troubling metrics this period. Fate Therapeutics's management did a relatively poor job managing cash and cash equivalents, which now sit at 64.7 and represents a -51.5% change from the last reporting period. This performance is significantly less impressive than its peers and competitors. Consequently, their cash and cash equivalents movement received a grade of 39. Also, Fate Therapeutics publishes concerning book value factor metrics in this report. price to book ratio (P/B) now sits at 3.9 and represents -52.7% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 22.6%. They does not yet appear to be headed in the right direction to achieve strong book value metrics. Disappointing results in book value factors typically precede negative pressure in stock prices, so its book value factors received a grade of 45. However, one encouraging metric, Assets, stood out. Fate Therapeutics's management was effective in managing the value of the assets on their balance sheet, which now sits at 858.4 and represents a -6.8% change from the previous report. This performance is interesting in comparison to its peers and competitors. The company's asset component, therefore, received a grade of 70. Therefore, it received a cautionary score of 53.

Parameter Value Change Score
Assets 858.4 -6.8% 70
Liabilities 225.0 -7.3% 63
Price to Book 3.9 -52.7% 45
Cash & Equivalents 64.7 -51.5% 39
Equity 633.4 -6.7% 54
* All values are TTM

The below chart describes Fate Therapeutics's performance as reflected on its balance sheet with respect to its peers. While Fate Therapeutics received a balance sheet score of 53, the average of its peers stands on 63.0.

  •  FATE
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 0 1
CureVac N.V. 2.6B 49 64 75 52 52 57 1 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 2 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 3 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 4 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 5 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 6 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 7 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 8 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 9 1
CareDx, Inc 1.2B 54 67 52 39 51 52 10 1
MannKind Corporation 957.2M 79 59 50 40 64 57 11 1
Merus N.V. 941.6M 59 68 50 83 81 70 12 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 13 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 14 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 15 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 16 1
Affimed N.V. 415.0M 56 66 63 56 47 54 17 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 18 1
AC Immune SA 299.8M 84 64 47 53 75 68 19 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 20 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 22 1
Amgen Inc. 130.1B 72 68 86 53 62 69 23 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 24 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 26 1
BioNTech SE 34.0B 75 69 64 97 73 75 27 1
Seagen Inc. 32.9B 59 68 55 43 66 61 28 1
Biogen Inc. 29.7B 57 72 92 50 76 76 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 30 1
Incyte Corporation 16.8B 71 72 95 82 79 83 31 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 32 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 33 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 34 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 35 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 36 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 37 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 38 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 39 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 40 1
Alkermes plc 5.0B 63 66 46 54 71 62 41 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 42 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 43 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 44 1
Natera, Inc. 3.6B 73 65 43 95 42 54 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 46 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 47 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 48 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 50 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 52 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 53 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 54 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 55 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 56 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 57 1
Vericel Corporation 1.1B 51 65 56 53 61 57 58 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 59 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 60 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 61 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 62 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 63 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 65 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 66 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 68 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 69 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 70 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 71 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 72 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 73 1
Geron Corporation 566.2M 69 72 37 59 62 60 74 1
Immatics N.V. 538.7M 56 70 84 95 73 76 75 1
Agenus Inc. 520.5M 73 62 37 55 60 54 76 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 77 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 78 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 79 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 80 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 81 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 82 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 83 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 84 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 85 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 92 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 93 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 94 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 95 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Fate Therapeutics's most recent income statement report was not encouraging. Fate Therapeutics management did an underwhelming job managing revenue efficiency this past period. Fate Therapeutics's revenue efficiency is 63.1 according to the metrics in the current filing, which represents a 13.0% change from the previous report. This metric might have a 13.1 percent impact on companies in the same industry and with the same market capitalization. Their revenue efficiency does not make a compelling case for upward pressure on the company's stock price. As a result, their revenue efficiency earned a score of 45. Also, Fate Therapeutics's EBIDTA now sits at -219.9 and represents -13.3% change from the last reporting period. This parameter coud affect companies in the same industry and market capitalization by up to 24.4%. Fate Therapeutics appears to be headed in the wrong direction in terms of EBITDA momentum, likely due to insufficient capital controls and a weaker than expected overall financial performance. Its EBITDA movement, therefore, received a grade of 52. However, one encouraging metric, Return Factors, stood out. Fate Therapeutics's reported return on equity (ROE) ratio was -32.7, representing a change of 18.1%. Its return factor metrics are even more remarkable when compared to their peers. The company's return factors (ROA & ROE) components, therefore, received a grade of 61. Therefore, its income statement earned a grade of 46.

Parameter Value Change Score
EBITDA -219.9 -13.3% 52
Total Revenues 63.1 13.0% 45
Return on Equity -32.7 18.1% 61
* All values are TTM

The below chart describes Fate Therapeutics's performance as reflected on its income statement with respect to its peers. While Fate Therapeutics received a income statement score of 46 , the average of its peers stands on 59.0.

  •  FATE
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 0 1
CureVac N.V. 2.6B 45 83 71 74 1 1
Abgenix Inc. 2.1B 47 47 47 47 2 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 3 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 4 1
Xencor, Inc. 1.6B 42 94 52 79 5 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 6 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 7 1
Veracyte, Inc. 1.4B 45 63 57 55 8 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 9 1
CareDx, Inc 1.2B 61 44 82 50 10 1
MannKind Corporation 957.2M 95 48 56 61 11 1
Merus N.V. 941.6M 48 60 59 54 12 1
Amarin Corporation plc 734.5M 95 44 82 63 13 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 14 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 15 1
Radius Health, Inc. 499.8M 94 71 68 82 16 1
Affimed N.V. 415.0M 95 49 75 66 17 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 18 1
AC Immune SA 299.8M 83 61 65 70 19 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 20 1
Chimerix, Inc. 178.4M 99 50 62 65 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 22 1
Amgen Inc. 130.1B 74 75 64 78 23 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 24 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 26 1
BioNTech SE 34.0B 41 89 75 79 27 1
Seagen Inc. 32.9B 54 65 70 62 28 1
Biogen Inc. 29.7B 90 57 73 70 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 30 1
Incyte Corporation 16.8B 59 77 60 73 31 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 32 1
United Therapeutics Corporation 10.6B 57 91 54 82 33 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 34 1
Exact Sciences Corporation 7.2B 57 67 54 62 35 1
Exelixis, Inc. 6.7B 54 91 54 81 36 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 37 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 38 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 39 1
Ascendis Pharma A/S 5.2B 38 68 46 54 40 1
Alkermes plc 5.0B 69 55 81 62 41 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 42 1
Novavax, Inc. 4.0B 41 89 54 75 43 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 44 1
Natera, Inc. 3.6B 52 51 78 52 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 46 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 47 1
Insmed Incorporated 2.4B 51 58 73 57 48 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 50 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 52 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 53 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 54 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 55 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 56 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 57 1
Vericel Corporation 1.1B 76 44 82 56 58 1
IVERIC bio, Inc. 1.1B 84 58 79 70 59 1
FibroGen, Inc. 1.0B 48 74 63 67 60 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 61 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 62 1
ImmunoGen, Inc. 946.1M 40 73 71 64 63 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 65 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 66 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 68 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 69 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 70 1
CTI BioPharma Corp. 603.6M 84 50 62 59 71 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 72 1
AnaptysBio, Inc. 586.3M 97 50 77 68 73 1
Geron Corporation 566.2M 89 67 73 78 74 1
Immatics N.V. 538.7M 37 93 53 77 75 1
Agenus Inc. 520.5M 57 83 45 74 76 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 77 1
Vaxart, Inc. 440.0M 99 51 72 68 78 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 79 1
MiMedx Group, Inc. 391.5M 87 43 83 59 80 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 81 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 82 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 83 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 84 1
Zymeworks Inc. 324.7M 58 53 77 56 85 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
Precigen, Inc. 299.1M 57 87 59 79 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
bluebird bio, Inc. 288.7M 99 91 61 96 92 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 93 1
MacroGenics, Inc. 184.6M 95 56 74 71 94 1
DermTech, Inc. 165.3M 49 48 78 52 95 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Fate Therapeutics appears likely to maintain its strong cash flow metrics and momentum going forward. Fate Therapeutics's management was effective in improving their net cash flow, which now sits at -41.7 and represents a -23.4% change from the previous report. Their net cash flow metrics are especially remarkable relative to their peers. The company's net cash flow, therefore, received a grade of 64. Also, Fate Therapeutics's published capital expenditures (CapEx) numbers were encouraging and reflected management's balanced change strategy. Fate Therapeutics recorded CapEx of -56.8, which represents -12.0% change from the previous report. This remarkable CapEx growth is expected to reinforce upward momentum for its's stock price going forward. Consequently, their CapEx movement received a grade of 55. However, one discouraging result, Asset Turnover, stood out. Asset turnover metrics during this period were surprisingly weak. Their reported asset turnover metrics of 0.1, which represents a -8.4% change from the previous report. Companies in the same sector and market capitalization will usually be affected by up to 4.1 percent by this parameter. Their asset turnover numbers are significantly less impressive when compared to their peers and competitors. Therefore, their asset turnover movement earned a score of 48. Consequently, its cash flow earned a score of 61.

Parameter Value Change Score
Net Cashflow -41.7 -23.4% 64
Capital Expenditure -56.8 -12.0% 55
Asset Turnover 0.1 -8.4% 48
Free Cashflow -2.7 -19.5% 52
* All values are TTM

The below chart describes Fate Therapeutics's performance as reflected on its cash flow with respect to its peers. While Fate Therapeutics received a cash flow score of 61, the average of its peers stands on 67.0.

  •  FATE
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 0 1
CureVac N.V. 2.6B 87 80 90 70 90 1 1
Abgenix Inc. 2.1B 66 53 45 59 58 2 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 3 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 4 1
Xencor, Inc. 1.6B 96 95 70 95 98 5 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 6 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 7 1
Veracyte, Inc. 1.4B 90 95 46 46 82 8 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 9 1
CareDx, Inc 1.2B 98 84 40 50 86 10 1
MannKind Corporation 957.2M 77 56 43 37 66 11 1
Merus N.V. 941.6M 70 71 74 53 71 12 1
Amarin Corporation plc 734.5M 52 40 74 55 55 13 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 14 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 15 1
Radius Health, Inc. 499.8M 64 40 37 56 57 16 1
Affimed N.V. 415.0M 72 57 95 43 74 17 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 18 1
AC Immune SA 299.8M 66 77 79 63 68 19 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 20 1
Chimerix, Inc. 178.4M 80 84 95 47 83 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 22 1
Amgen Inc. 130.1B 80 74 67 74 81 23 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 24 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 26 1
BioNTech SE 34.0B 73 97 50 52 72 27 1
Seagen Inc. 32.9B 53 53 50 87 58 28 1
Biogen Inc. 29.7B 58 54 90 73 66 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 30 1
Incyte Corporation 16.8B 78 79 92 74 84 31 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 32 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 33 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 34 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 35 1
Exelixis, Inc. 6.7B 79 90 89 83 87 36 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 37 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 38 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 39 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 40 1
Alkermes plc 5.0B 89 95 76 80 92 41 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 42 1
Novavax, Inc. 4.0B 62 38 63 54 60 43 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 44 1
Natera, Inc. 3.6B 52 54 56 84 58 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 46 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 47 1
Insmed Incorporated 2.4B 79 80 61 89 82 48 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 50 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 52 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 53 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 54 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 55 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 56 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 57 1
Vericel Corporation 1.1B 64 46 59 73 65 58 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 59 1
FibroGen, Inc. 1.0B 86 74 48 87 84 60 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 61 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 62 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 63 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 65 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 66 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 68 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 69 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 70 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 71 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 72 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 73 1
Geron Corporation 566.2M 78 68 49 81 77 74 1
Immatics N.V. 538.7M 82 95 56 99 86 75 1
Agenus Inc. 520.5M 57 43 52 77 58 76 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 77 1
Vaxart, Inc. 440.0M 72 56 53 38 65 78 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 79 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 80 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 81 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 82 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 83 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 84 1
Zymeworks Inc. 324.7M 52 65 45 83 57 85 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
Precigen, Inc. 299.1M 82 75 37 85 74 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 92 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 93 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 94 1
DermTech, Inc. 165.3M 60 51 45 86 58 95 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.